Efficacy and Safety Study of the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis

Trial Identifier: D3256C00001
Sponsor: AstraZeneca
Collaborator:
IQVIA
NCTID:: NCT04605094
Start Date: November 2020
Primary Completion Date: April 2022
Study Completion Date: September 2022
Condition: Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Bulgarian Translation
Czech Translation
English Translation
Spanish Translation
French Translation
Korean Translation
Polish Translation

Trial Locations

Country Location
AU Kogarah, AU, 2217
AU Parkville, AU, 3050
AU Sippy Downs, AU, 4556
AU Woolloongabba, AU, 04102
BG Haskovo, BG, 6300
BG Pleven, BG, 5800
BG Sofia, BG, 1431
BG Sofia, BG, 1000
CZ Brno, CZ, 602 00
CZ Ostrava, CZ, 702 00
CZ Ostrava-Poruba, CZ, 708 52
CZ Pardubice, CZ, 530 02
CZ Praha, CZ, 110 00
ES Alicante, ES, 03010
ES Barcelona, ES, 08041
ES Cordoba, ES, 14004
ES Madrid, ES, 28040
ES Manises, ES, 46940
FR Brest Cedex 2, FR, 29609
FR LILLE CEDEX, FR, 59037
KR Ansan-si, KR, 15355
KR Daegu, KR, 41944
KR Gwangju, KR, 61453
KR Seongnam-si, KR, 13620
KR Seoul, KR, 05278
KR Seoul, KR, 5030
KR Seoul, KR, 06591
KR Seoul, KR, 05505
KR Seoul, KR, 04763
KR Seoul, KR, 06973
KR Seoul, KR, 07441
KR Yangsan-si, KR, 50612
PL Krakow, PL, 30-033
PL Lodz, PL, 90-302
PL Osielsko, PL, 86031
PL Poznań, PL, 60-214
PL Warszawa, PL, 01-262
US, CA Los Angeles, CA, US, 90025
US, CA Newport Beach, CA, US, 92663
US, CT Bridgeport, CT, US, 06606
US, FL Fort Myers, FL, US, 33912
US, FL Tampa, FL, US, 33606
US, FL Tampa, FL, US, 33607
US, MI Ypsilanti, MI, US, 48197
US, NH Portsmouth, NH, US, 03801
US, NY New York, NY, US, 10029
US, NY Rochester, NY, US, 14620
US, OH Cincinnati, OH, US, 45219
US, OK Norman, OK, US, 73071
US, PA Sugarloaf, PA, US, 18249